DAFTAR PUSTAKA

Ağçam, E., Akyildiz, A., Kamat, S., & Balasubramaniam, V. M. (2021). Bioactive Compounds Extraction from the Black Carrot Pomace with Assistance of High Pressure Processing: An Optimization Study. *Waste and Biomass Valorization*, *12*, 1–19. https://doi.org/10.1007/s12649-021-01431-z

Al-Anazi, M; Khairuddean, M; Al-Najjar, B; Algarni, A.S; Alshehri, O.M; Aziz, M.A. Identification of anti-cancer bioactive compounds using molecular docking and pharmacokinetics profiling from traditional medicinal plants. Saudi J Biol Sci 2023, 30(2), 102789, https://doi.org/10.1016/j.sjbs.2022.102789.

Baeshen, N. A., Almulaiky, Y. Q., Afifi, M., Al-Farga, A., Ali, H. A., Baeshen, N. N., Abomughaid, M. M., Abdelazim, A. M., & Baeshen, M. N. (2023). GC-MS Analysis of Bioactive Compounds Extracted from Plant Rhazya stricta Using Various Solvents. *Plants*, *12*(4). https://doi.org/10.3390/plants12040960

Cavallaro, P. A., De Santo, M., Belsito, E. L., Longobucco, C., Curcio, M., Morelli, C., Pasqua, L., & Leggio, A. (2023). Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics. *Nanomaterials*, *13*(17). https://doi.org/10.3390/nano13172476

Chen, F; Yin, X; Wang, Y; Lv, Y; Sheng, S; Ouyang, S; Zhong, Y. Pharmacokinetics, tissue distribution, and druggability prediction of the natural anticancer active compound cytisine n-isoflavones combined with computer simulation. Biol Pharm Bull 2020, 43(6), 976-984.

Chen, J; Xie, J; Liang, Z; Wang, L; Wei, Y; Luo, X; Li, X. Molecular docking and dynamics simulation of bioactive compounds from *Ginkgo biloba* against breast cancer. Front Pharmacol 2022, 13, 843201, https://doi.org/10.3389/fphar.2022.843201

Crowley, L. C., Marfell, B. J., Scott, A. P., & Waterhouse, N. J. 2016. Quantitation of Apoptosis and Necrosis by Annexin V Binding, Propidium Iodide Uptake, and Flow Cytometry. Cold Spring Harbor Protocols, 2016(11). https://doi.org/10.1101/pdb. prot087288

Ekins, S., Mestres, J., & Testa, B. (2007). In silico pharmacology for drug discovery: Methods for virtual ligand screening and profiling. In *British Journal of Pharmacology* (Vol. 152, Issue 1, pp. 9–20). https://doi.org/10.1038/sj.bjp.0707305

Elshaer, N.S.M; Mahmoud, A.A; Kandil, Z.A; et al. Computational-based discovery and pharmacokinetics evaluation of herbal compounds as potential inhibitors of estrogen receptors. J Chem Inf Model. 2023, 63(3), 1409-1423, https://doi.org/10.1021/acs.jcim.2c01234.

García-Sánchez, M; Miranda-Ramos, V; Martínez-Castañeda, J.S; et al. Predicting bioavailability and potential bioactivity of Mexican traditional medicinal plants using in silico models. Plants 2021, 10(4), 749. https://doi.org/10.3390/plants10040749.

Hendrarti, W., Umar, A. H., Syahruni, R., Rafi, M., & Kusuma, W. A. (2024). Deciphering the Mechanism of Action Cosmos caudatus Compounds Against Breast Neoplasm : A Combination of Pharmacological Networking and Molecular Docking Approach with Bibliometric Analysis. *Indonesian Journal of Science & Technology*, *9*, 527–556.

Hotmian, E., Suoth, E., Fatimawali, F., & Tallei, T. (2021). ANALISIS GC-MS (GAS CHROMATOGRAPHY - MASS SPECTROMETRY) EKSTRAK METANOL

DARI UMBI RUMPUT TEKI (Cyperus rotundus L.). *Pharmacon*, *10*(2), 849. https://doi.org/10.35799/pha.10.2021.34034

Iqbal, N., & Iqbal, N. (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Molecular Biology International*, *2014*, 1–9. https://doi.org/10.1155/2014/852748

Jackson, C., Finikarides, L., & Freeman, A. L. J. (2022). The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis. *PLoS ONE*, *17*(12 December), 1–20. https://doi.org/10.1371/journal.pone.0275321

Micera, M., Botto, A., Geddo, F., Antoniotti, S., Bertea, C. M., Levi, R., Gallo, M. P., & Querio, G. (2020). Squalene: More than a step toward sterols. *Antioxidants*, *9*(8), 1–14. https://doi.org/10.3390/antiox9080688

Panigroro, S., Hernowo, B. S., & Purwanto, H. (2019). Breast Cancer Treatment Guideline. *Jurnal Kesehatan Masyarakat*, *4*(4), 1–50. http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf

Raab, G., & Eiermann, W. (2000). Trastuzumab. *Tagliche Praxis*, *41*(4), 895–898. https://doi.org/10.2217/17455057.1.2.161

Rahim, A., Saito, Y., Fukuyoshi, S., Miyake, K., Goto, M., Chen, C. H., Alam, G., Lee, K. H., & Nakagawa-Goto, K. (2020). Paliasanines A-E, 3,4-Methylenedioxyquinoline Alkaloids Fused with a Phenyl-14-oxabicyclo[3.2.1]octane Unit from Melochia umbellata var. deglabrata. *Journal of Natural Products*, *83*(10), 2931–2939. https://doi.org/10.1021/acs.jnatprod.0c00454

Rampogu, S., Son, M., Baek, A., Park, C., Rana, R. M., Zeb, A., Parameswaran, S., & Lee, K. W. (2018). Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches. *Computational Biology and Chemistry*, *74*, 327–338. https://doi.org/10.1016/j.compbiolchem.2018.04.002

Rasul, H.O; Aziz, B.K; Ghafour, D.D; Kivrak, A. In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer. J Mol Model 2022, 28(1),17.

Renadi, S., Pratita, A. T. K., Mardianingrum, R., & Ruswanto, dan R. (2023). The Potency of Alkaloid Derivates as Anti-Breast Cancer Candidates: In Silico Study. *Jurnal Kimia Valensi*, *9*(1), 89–108. https://doi.org/10.15408/jkv.v9i1.31481

Reyhani, M. mehdi, Minaeefar, A. abbas, Dadfar, F., & Bamdad, K. (2023). Evaluation and Simulation of Docking Peptide Labeled with Technetium-99m (Tc-99m) with Human Epidermal Growth Factor Receptor 2 (HER2) in HER2-Positive Breast Cancer Cells. *Jentashapir Journal of Cellular and Molecular Biology*, *14*(4). https://doi.org/10.5812/jjcmb-139817

Saravanan, R., Raja, K., & Shanthi, D. (2022). GC–MS Analysis, Molecular Docking and Pharmacokinetic Properties of Phytocompounds from Solanum torvum Unripe Fruits and Its Effect on Breast Cancer Target Protein. *Applied Biochemistry and Biotechnology*, *194*(1), 529–555. https://doi.org/10.1007/s12010-021-03698-3

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Tayeb, R., Rahim, A., Alam, G., Wahyuono, S., & Hartati, M. S. (2005). Fraksinasi Senyawa Antikanker Daun Paliasa (Melochia umbellata (Houtt) Staff Var. deglabrata. *Majalah Farmasi Dan Farmakologi*, *11*, 61–71.

Tsujimoto, M. (1916). A HIGHLY UNSATURATED HYDROCARBON IN SHARK LIVER OIL. *Journal of Industrial & Engineering Chemistry*, *8*(10), 889–896. https://doi.org/10.1021/i500010a005

Umar, A. H., Ratnadewi, D., Rafi, M., Sulistyaningsih, Y. C., Hamim, H., & Kusuma, W. A. (2023). Drug candidates and potential targets of Curculigo spp. compounds for treating diabetes mellitus based on network pharmacology, molecular docking and molecular dynamics simulation. *Journal of Biomolecular Structure & Dynamics*, *41*(17), 8544–8560. https://doi.org/10.1080/07391102.2022.2135597

Usman. (2020). Senyawa Triterpenoid dari Kulit Batang Melochia umbellata dan Bioaktivitasnya. *Jurnal Sains Kesehatan*, *2*(4). https://doi.org/10.25026/jsk.v2i4.153

Valéra, M.C; Fontaine, C; Dupuis, M; Noirrit-Esclassan, E; Vinel, A; Guillaume, M; et al. Towards optimization of estrogen receptor modulation in medicine. Pharmacol Ther 2018, 189, 123-129.

Wali Sait, K. H. (2020). Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agents. *Bioinformation*, *16*(11), 882. https://doi.org/10.6026/97320630016882

WHO. (2020). *Cancer Indonesia 2020 Country Profile*. https://doi.org/10.1016/S0366-0850(07)80117-7

Widiandani, T., Tandian, T., Zufar, B. D., Suryadi, A., Purwanto, B. T., Hardjono, S., & Siswandono. (2023). In vitro study of pinostrobin propionate and pinostrobin butyrate: Cytotoxic activity against breast cancer cell T47D and its selectivity index. *Journal of Public Health in Africa*, *14*(S1), 97–102. https://doi.org/10.4081/jphia.2023.2516

Xi, J. Ultrahigh pressure extraction of bioactive compounds from plants—A review. Crit Rev Food Sci Nutr. 2017, 57(6), 1097-1106

Zhang, K., Wu, X., Luo, H., Yang, S., Chen, J., Chen, W., Chen, J., Mo, Y., Li, L., & Wang, W. (2021). Biochemical pathways and enhanced degradation of dioctyl phthalate (DEHP) by sodium alginate immobilization in MBR system. *Water Science and Technology*, *83*(3), 664–677. https://doi.org/10.2166/wst.2020.605

LAMPIRAN

Lampiran 1. Skema kerja



Lampiran 2. Dokumentasi

Gambar 9. Pengambilan sampel

Gambar 10. Penyiapan simplisia

Gambar 11. Ekstraksi dengan metode HPE

Gambar 12. Freeze Drying

Gambar 13. Ekstraksi dengan metode MAE

Gambar 14. Ekstraksi dengan metode Infusa



Gambar 15. Analisis GC-MS



Gambar 16. Pengujian *in silico*



Gambar 17. Pengujian *in vitro*

Lampiran 3. Pengujian IC_{50}

Pengujian WST-1 (Kontrol dan Cisplatin)

Perlakuan	Abs 1	Abs 2	Abs 3	Rata-Rata
Control	0,5343	0,3651	0,1084	0,335933333
WST	0,1030	0,0993	0,1016	0,1013

***M. Umbellata* HPE 200**

Konsentrasi	Abs 1	Abs 2	Abs 3
31,25 µg	0,5877	0,5091	0,4319
62,5 µg	0,4335	0,3628	0,2956
125 µg	0,1399	0,1306	0,1263
250 µg	0,1277	0,1609	0,1261
500 µg	0,1126	0,1080	0,1107

***M. Umbellata* HPE 400**

Konsentrasi	Abs 1	Abs 2	Abs 3
31,25 µg	0,3689	0,3446	0,3331
62,5 µg	0,2783	0,1997	0,2313
125 µg	0,1221	0,1220	0,1190
250 µg	0,1091	0,1144	0,1210
500 µg	0,1053	0,1140	0,1113

***M. Umbellata* HPE 600**

Konsentrasi	Abs 1	Abs 2	Abs 3
31,25 µg	0,2235	0,4286	0,6242
62,5 µg	0,1706	0,3761	0,6194
125 µg	0,1154	0,2147	0,5405
250 µg	0,1476	0,1230	0,2826
500 µg	0,1111	0,1127	0,1091

$$\%\text{Sel Hidup} = \frac{\text{Absorbansi Sampel - Absorbansi Medium}}{\text{Absorbansi Kontrol - Absorbansi Medium}} \times 100\%$$

Session name	WST1 Assay (25-9-2024).skax
Session notes	Protocol for reading w/ 450nm
Software version	SkanIt Software RE for Microplate Readers RE, ver. 6.1.0.51
Execution time	25/09/2024 21:01:02

Persamaan Regresi Linear *M. Umbellata* HPE 200

y = -1,6959x + 223,38

R^2 = 0,9965

***M. Umbellata* HPE 200**

Konsentrasi	Persentase Sel Hidup			Rata-Rata	SD	IC_{50} (µg/mL)
31,25 µg	2,073022	1,738031	1,409007	174,0019889	33,20118554	
62,5 µg	1,415826	1,114505	0,828101	111,9477198	29,3894313	
125 µg	0,164512	0,124876	0,106549	13,19789743	2,962707191	102,234802
250 µg	0,112516	0,254013	0,105697	15,74087228	8,373151319	
500 µg	0,04816	0,028555	0,044006	3,89259838	0,985181898	

Persamaan Regresi Linear *M. Umbellata* HPE 400

y = -1,0002x + 130,1

R^2 = 0,967

***M. Umbellata* HPE 400**

Konsentrasi	Persentase Sel Hidup			Rata-Rata	SD	IC_{50} (µg/mL)
31,25 µg	1,140503	1,036937	0,987924	105,5121466	7,789771071	
62,5 µg	0,754369	0,419378	0,554056	57,59340815	16,8563614	
125 µg	0,088649	0,088223	0,075437	8,410285552	0,750800413	80,0839832
250 µg	0,033243	0,055832	0,083961	5,767864754	2,540910493	
500 µg	0,017048	0,054127	0,04262	3,793152436	1,897892662	

Persamaan Regresi Linear *M. Umbellata* HPE 600

y = -0,6229x + 159,13

R^2 = 0,9954

***M. Umbellata* HPE 600**

Konsentrasi	Persentase Sel Hidup			Rata-Rata	SD	IC_{50} (µg/mL)
31,25 µg	0,520813	1,394942	2,228584	138,1446228	85,39654853	
62,5 µg	0,295354	1,171189	2,208126	122,4889899	95,75159149	
125 µg	0,060094	0,483307	1,871857	80,50859497	94,77750016	175,196661
250 µg	0,197329	0,092485	0,772695	35,41696264	36,62249254	
500 µg	0,041767	0,048586	0,033243	4,119903395	0,768731312	


M. umbellata HPE 200 Mpa
Mean
200
150
100
50
0
0
20
40
60
80
100
120
140
Concentration
y = -1,6959x + 223,38
R² = 0,9965


M. umbellata HPE 400 Mpa
Mean
120
100
80
60
40
20
0
0
20
40
60
80
100
120
140
Concentration
y = -1,0002x + 130,1
R² = 0,967


M. umbellata HPE 600 Mpa
Mean
160
140
120
100
80
60
40
20
0
0
20
40
60
80
100
120
140
Concentratuin
y = -0,6229x + 159,13
R² = 0,9954

Lampiran 4. Hasil Pengujian Apoptosis Sel

Quadrant Statistics

File: Data.006
Sample ID: kontsel.2
Tube: Ann V/PI
Acquisition Date: 09-Oct-24
Gated Events: 6111
X Parameter: Annexin V FITC (Log)
Quad Location: 19, 12

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 16129
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	382	6.25	2.37	9.46	8.79	36.62	29.14
UR	117	1.91	0.73	65.50	47.76	42.60	30.22
LL	5149	84.26	31.92	6.84	6.01	3.85	3.42
LR	463	7.58	2.87	40.97	35.31	4.61	4.00

Quadrant Statistics

File: Data.007
Sample ID: kontcisp.2
Tube: Ann V/PI
Acquisition Date: 09-Oct-24
Gated Events: 680
X Parameter: Annexin V FITC (Log)
Quad Location: 19, 12

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 26882
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	7	1.03	0.03	13.55	13.42	38.95	20.40
UR	260	38.24	0.97	91.70	79.83	25.04	22.20
LL	257	37.79	0.96	11.14	10.29	5.26	4.83
LR	156	22.94	0.58	47.02	38.25	7.74	7.37

Quadrant Statistics

File: Data.008
Sample ID: 1/2IC.2
Tube: Ann V/PI
Acquisition Date: 09-Oct-24
Gated Events: 3017
X Parameter: Annexin V FITC (Log)
Quad Location: 19, 12

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 14630
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	1277	42.33	8.73	12.90	12.46	54.42	46.70
UR	687	22.77	4.70	35.23	29.63	76.99	65.22
LL	961	31.85	6.57	9.26	8.56	5.30	4.71
LR	92	3.05	0.63	31.56	28.25	6.73	5.84

Quadrant Statistics

File: Data.009
Sample ID: IC.2
Tube: Ann V/PI
Acquisition Date: 09-Oct-24
Gated Events: 65
X Parameter: Annexin V FITC (Log)
Quad Location: 18, 10

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 29295
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	6	9.23	0.02	12.93	12.30	39.00	31.29
UR	55	84.62	0.19	180.12	135.17	218.58	136.46
LL	3	4.62	0.01	14.35	14.16	6.47	6.42
LR	1	1.54	0.00	19.28	19.28	3.49	3.49

Quadrant Statistics

File: Data.010
Sample ID: 2IC.2
Tube: Ann V/PI
Acquisition Date: 09-Oct-24
Gated Events: 385
X Parameter: Annexin V FITC (Log)
Quad Location: 19, 12

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 9450
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	1	0.26	0.01	17.62	17.62	40.32	40.32
UR	382	99.22	4.04	163.91	126.17	129.91	61.79
LL	2	0.52	0.02	8.07	5.91	3.16	2.90
LR	0	0.00	0.00	***	***	***	***

Quadrant Statistics

File: Data.001
Sample ID: kontsel.1
Tube: Ann V/PI
Acquisition Date: 10-Oct-24
Gated Events: 10470
X Parameter: Annexin V FITC (Log)
Quad Location: 14, 22

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 13557
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	207	1.98	1.53	7.36	6.64	265.11	85.05
UR	42	0.40	0.31	71.37	46.31	324.28	114.37
LL	10214	97.55	75.34	3.75	3.48	6.24	5.45
LR	7	0.07	0.05	15.63	15.56	18.11	17.94

Quadrant Statistics

File: Data.007
Sample ID: kontcisp.2
Tube: Ann V/PI
Acquisition Date: 10-Oct-24
Gated Events: 5116
X Parameter: Annexin V FITC (Log)
Quad Location: 14, 22

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 18711
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	397	7.76	2.12	7.99	7.18	234.84	118.52
UR	202	3.95	1.08	33.03	22.37	223.29	113.93
LL	4473	87.43	23.91	4.65	4.19	4.90	4.12
LR	44	0.86	0.24	16.39	16.13	16.09	15.73

Quadrant Statistics

File: Data.008
Sample ID: 1/2IC.2
Tube: Ann V/PI
Acquisition Date: 10-Oct-24
Gated Events: 7125
X Parameter: Annexin V FITC (Log)
Quad Location: 14, 22

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 14925
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	145	2.04	0.97	7.74	6.99	382.83	126.16
UR	141	1.98	0.94	34.87	26.35	225.12	74.45
LL	6776	95.10	45.40	4.18	3.81	4.47	3.90
LR	63	0.88	0.42	17.54	17.39	17.87	17.65

Quadrant Statistics

File: Data.009
Sample ID: IC.2
Tube: Ann V/PI
Acquisition Date: 10-Oct-24
Gated Events: 9095
X Parameter: Annexin V FITC (Log)
Quad Location: 14, 22

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 14322
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	140	1.54	0.98	7.82	7.08	175.37	79.64
UR	212	2.33	1.48	53.81	32.71	195.74	63.60
LL	8662	95.24	60.48	4.46	4.07	4.67	4.08
LR	81	0.89	0.57	19.64	19.00	16.50	15.88

Quadrant Statistics

File: Data.010
Sample ID: 2IC.2
Tube: Ann V/PI
Acquisition Date: 10-Oct-24
Gated Events: 9191
X Parameter: Annexin V FITC (Log)
Quad Location: 16, 20

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 14594
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	272	2.96	1.86	8.62	7.77	571.81	204.13
UR	542	5.90	3.71	37.39	31.18	100.17	45.62
LL	8329	90.62	57.07	4.80	4.34	5.22	4.57
LR	48	0.52	0.33	18.57	18.48	17.44	17.26

Quadrant Statistics

File: Data.006
Sample ID: kont.cisp.2
Tube: Ann V/PI
Acquisition Date: 11-Oct-24
Gated Events: 905
X Parameter: Annexin V FITC (Log)
Quad Location: 27, 25

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 5490
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	133	14.70	2.42	11.85	9.67	205.36	88.22
UR	19	2.10	0.35	44.67	39.52	137.38	90.24
LL	752	83.09	13.70	6.72	5.86	5.61	4.14
LR	1	0.11	0.02	27.88	27.88	13.46	13.46

Quadrant Statistics

File: Data.002
Sample ID: kontcisp.1
Tube: Ann V/PI
Acquisition Date: 11-Oct-24
Gated Events: 3847
X Parameter: Annexin V FITC (Log)
Quad Location: 27, 13

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 11925
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	366	9.51	3.07	16.98	15.90	41.11	26.58
UR	403	10.48	3.38	107.49	53.77	117.23	39.41
LL	3068	79.75	25.73	10.50	9.43	6.20	5.64
LR	10	0.26	0.08	30.93	30.48	11.24	10.90

Quadrant Statistics

File: Data.003
Sample ID: 1/2IC.1
Tube: Ann V/PI
Acquisition Date: 11-Oct-24
Gated Events: 9693
X Parameter: Annexin V FITC (Log)
Quad Location: 25, 16

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 14339
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	483	4.98	3.37	15.72	14.64	47.06	27.12
UR	1338	13.80	9.33	75.13	64.12	63.55	44.99
LL	7792	80.39	54.34	7.57	6.80	6.04	5.20
LR	80	0.83	0.56	30.68	30.33	12.87	12.49

Quadrant Statistics

File: Data.004
Sample ID: IC.1
Tube: Ann V/PI
Acquisition Date: 11-Oct-24
Gated Events: 9623
X Parameter: Annexin V FITC (Log)
Quad Location: 27, 25

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 14552
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	223	2.32	1.53	17.58	16.46	75.44	47.87
UR	1631	16.95	11.21	112.40	92.49	112.75	84.30
LL	7669	79.69	52.70	8.32	7.33	7.50	6.54
LR	100	1.04	0.69	35.99	34.45	16.89	15.95

Quadrant Statistics

File: Data.005
Sample ID: 2IC.1
Tube: Ann V/PI
Acquisition Date: 11-Oct-24
Gated Events: 2731
X Parameter: Annexin V FITC (Log)
Quad Location: 27, 25

Log Data Units: Linear Values
Patient ID: kultur T47D - 24 jam
Panel: Untitled Acquisition Tube List
Gate: G1
Total Events: 6330
Y Parameter: Propidium Iodide (Log)

Quad	Events	% Gated	% Total	X Mean	X Geo Mean	Y Mean	Y Geo Mean
UL	10	0.37	0.16	22.08	21.29	93.29	49.67
UR	1183	43.32	18.69	163.44	134.92	83.88	60.87
LL	1260	46.14	19.91	11.64	10.54	5.37	4.88
LR	278	10.18	4.39	59.23	53.44	15.61	14.51